Is Melanotan II with PT-141 legal in Australia?

Two melanocortin agonists run together, one of which is the active metabolite of the other. That is the whole problem: bremelanotide is what melanotan II becomes in the body, so this is one drug class hit twice, with the pigment-inducing parent and its approved metabolite in the same session. Vial sizes are not consistent and the combination has never been studied.

Bremelanotide, sold as PT-141, is a metabolite of melanotan II. That relationship is the reason both exist and it is the reason stacking them makes very little pharmacological sense.

Mechanism: Both are non-selective melanocortin receptor agonists. Bremelanotide acts largely through melanocortin 4 receptor signalling in the central nervous system, which is the sexual desire pathway.

Regulatory history: Bremelanotide is FDA approved for hypoactive sexual desire disorder in premenopausal women. Melanotan II is not approved anywhere and has been the subject of regulator warnings in several countries.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Melanotan II with PT-141 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.